Vaccine Politics and Policy Have Gone Off the Rails. Let’s Hope Reimbursement Stays on Track

I don’t think there is a whole lot of analysis needed on the Commonwealth Fund’s look at the impact of high health care costs on consumers. A majority of the

It’s a big 340B day, starting with a decision by a federal appeals court to side with Arkansas in a dispute with PhRMA.  Arkansas has a law that says that

Sorry for the surprise absence of Cost Curve yesterday. Turns out, there really wasn’t much to say, and I didn’t want to clog your inbox. Speaking of absences, Cost Curve